Endogenous interstitial adenosine in isolated myenteric neural networks varies inversely with prevailing PO2.
Isolated myenteric ganglion networks were used in a perifusion protocol to characterize the response of interstitial adenosine levels to changes in prevailing PO2. The biological activity of such adenosine was assessed using inhibition of release of substance P (SP) as a functional measure of adenosine activity, and the effect of altered O2 tension on both spontaneous and elevated extracellular K+ concentration-evoked SP release from networks was determined over a range of PO2 values from hypoxic (PO2 = 54 mmHg) to hyperoxic (PO2 = 566 mmHg). Release of SP was found to be sensitive to PO2, and a linear graded relationship was obtained. Perifusion in the additional presence of the adenosine A1-receptor-selective antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) revealed considerable adenosinergic inhibition with an inverse exponential relationship and hyperoxic threshold PO2. Disinhibition of evoked SP release by DPCPX in the absence of TTX was double that observed in its presence, indicating a neural source for some of the adenosine released during hypoxia. A postulated neuroprotective role for adenosine is consistent with the demonstrated relationship between interstitial adenosine and prevailing O2 tension.
Deshpande
N A
NA
Department of Pharmacology and Toxicology, University of Western Ontario, London, Ontario, Canada N6A 5C1.
McDonald
T J
TJ
Cook
M A
MA
D000241:Adenosine / Q000378:metabolism*; D000818:Animals; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D066298:In Vitro Techniques; D007700:Kinetics; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D009415:Nerve Net / Q000187:drug effects / Q000502:physiology*; D010100:Oxygen / Q000494:pharmacology*; D010313:Partial Pressure; D058915:Purinergic P1 Receptor Antagonists; D013373:Substance P / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013779:Tetrodotoxin / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology*
D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines; D013373:Substance P; D013779:Tetrodotoxin; C051360:1,3-dipropyl-8-cyclopentylxanthine; D000241:Adenosine; D010100:Oxygen